Categories Analysis, Earnings, Health Care, LATEST

Earnings Preview: GW Pharma to widen losses in to-be-reported quarter

GW Pharmaceuticals PLC (GWPH) is expected to post its quarterly earnings on Feb. 26.

Last week, GW Pharma saw its stock slide 1.32% in a day to close at $143.95 on Wednesday. But when it opened for trading the very next day, it was to be noted that shares had grown 7.5% in a month. This growth has clearly outpaced the medical sector which moved up just 3% in the same period.

GW Pharma is expected to post a quarterly loss of $2.97 per share, indicating a 22% slide from same time a year ago, on revenue of $7.10 million. However, this could see a change given that the company is shifting its earnings reporting to a new fiscal year-ending Dec. 31, 2018.

Investing in pot stocks 101: Here’s what you should know

LOOKING BACK

In the previously reported fourth quarter of the last fiscal cycle, GW Pharma stock slipped 4% in after-hours trading after the company missed analyst estimates for the period. Sales for the biopharma firm dipped 1% to $2.42 million on flat product sales, and revenues failed to beat street consensus.

The company’s loss widened 28% to $0.23 per share, on increased selling, general and administrative (SG&A) expenses.

On Nov. 26, GW’s frontline cannabinoid drug Epidiolex posted positive results in the second Phase-3 trial for treating patients diagnosed with the Dravet syndrome, a rare form of epilepsy which causes seizures right from childhood. It is estimated that there are 2.2 million people in the US who suffer from epilepsy and nearly 470,000 are children.

Epidiolex was approved by the US FDA in June 2018 to treat patients suffering from seizures relating to Dravet syndrome or Lennox-Gastaut syndrome (LGS). The company filed a marketing authorization application with the European Medicines Agency (EMA) and expects to receive approval from the regulator by the first quarter of 2019.

Also Read:  United Natural Foods Q2 earnings and sales tops estimates

Epidiolex competes with Fintepla from Zogenix (ZGNX). Fintepla is a low-dose fenfluramine formulation drug to treat patients with Dravet syndrome. Zogenix has kickstarted the rolling submission of new drug application filing to FDA for treating patients with the Dravet syndrome. The low-dose fenfluramine drug has also shown positive results in LGS with Zogenix is currently enrolling patients for phase 3 clinical trial of Fintepla for patients diagnosed with LGS.

 

We’re on Apple News! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Most Popular

MongoDB (MDB) has what it takes to end the losing streak. Here’s why

An innovative product portfolio that is capable of outshining the legacy databases has helped MongoDB (NASDAQ: MDB) stay largely unaffected by the market turmoil so far. Of late, the database

Macy’s (M) confirms Q1 loss; expects gradual sales recovery

Retailer Macy's (NYSE: M) posted mixed results for its first quarter of 2020. While the topline missed the market's estimates, bottom line topped the targets. There were no change in

STZ Earnings: Key quarterly highlights that you need to know from Constellation Brands Q1 financial results

Constellation Brands (NYSE: STZ) today announced its first quarter financial results for the period ended May 31, 2020. First quarter net loss was $177.9 million, or $0.94 per share, compared

Top